rsv vaccine - Search News

Order byBest matchMost fresh

RFK Jr. fires ‘Washingtonian of year’ from CDC vaccine panel

US CDC official in charge of COVID, RSV data resigns ahead of vaccine meeting

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used to shape national vaccine policy has resigned, citing concerns over how such data would be used by the Trump administration.

· 15h · on MSN

CDC virus expert resigns after RFK Jr.’s purge of vaccine advisers

· 13h · on MSN

CDC vaccine advisers who were removed from committee by RFK Jr. speak out

· 1d

How one meeting in 2020 and a GOP senator helped create RFK Jr.’s vaccine wreck

Liberal ideology and Republican politics laid groundwork for Kennedy’s remaking of the CDC’s vaccine panel.

· 20h

Who Is on RFK, Jr.’s New Vaccine Panel—And What Will They Do?

Boise State Public Radio · 1d

A doctor fired by RFK Jr. from the national vaccine advisory board speaks out

3don MSN

FDA expands approval of Moderna's RSV vaccine to some adults under age 60

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

MPR15h

RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

3don MSN

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The mRNA-based RSV shot,

STAT4d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.

Explore more

PMLive23h

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) for use in adults aged 18 to 59 years who are at an increased risk of RSV-caused lower respiratory tract disease (LRTD).

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world,

3don MSN

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

India Today on MSN1d

Why RSV prevention for infants is still years away in India

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges in India but show promising progress.